Higher education in Financial Engineering and Money & Capital Markets. SPK (Turkey CMB) licence. 16 years across institutional markets, research, and quant-driven analytics.
AI summary
TORONTO and GERMANTOWN, Md., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics Inc. ("Sernova") (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO) and Seraxis Holdings, Inc. ("Seraxis") today announced a definitive agreement to combine their technologies and businesses to create a clinical-stage company, BetaNova Biotherapeutics ("BetaNova") focused on advancing a differentiated approach to type 1 diabetes (T1D) islet cell replacement (the "Merger"). BetaNova will be a U.S.-domiciled biotechnology company headquartered in Germantown, Maryland, with integrated research laboratories and cGMP manufacturing capabilities. Upon completion of the Merger, the shareholders of Seraxis and Sernova will each own approximately 50% of BetaNova.
AI commentary is generated from public news feeds and is not investment advice.